Reduced Mortality Risk After THA, TKA

In July, Healio reported that “use of rivaroxaban after total hip or knee arthroplasty led to lower mortality risk and decreased reoperation rates due to infection or hematomas compared with low-molecular-weight heparin.” The original research was presented during the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Virtual Congress, June 30-July 2, 2021. Read the full article here.